Ariad Pharmaceuticals (ARIA): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Ariad Pharmaceuticals ( ARIA) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.4%. By the end of trading, Ariad Pharmaceuticals fell $0.65 (-3.2%) to $19.37 on light volume. Throughout the day, 1,644,441 shares of Ariad Pharmaceuticals exchanged hands as compared to its average daily volume of 2,695,100 shares. The stock ranged in price between $19.25-$20.11 after having opened the day at $20.00 as compared to the previous trading day's close of $20.02. Other companies within the Health Care sector that declined today were: Mast Therapeutics ( MSTX), down 34.6%, Oxygen Biotherapeutics ( OXBT), down 23.9%, CEL-SCI Corporation ( CVM), down 17.1% and Senesco Technologies ( SNTI), down 12.7%.

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. Ariad Pharmaceuticals has a market cap of $3.7 billion and is part of the drugs industry. Shares are up 4.3% year to date as of the close of trading on Friday. Currently there are 14 analysts that rate Ariad Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Ariad Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.

On the positive front, Biocryst Pharmaceuticals ( BCRX), up 51.2%, TrovaGene ( TROV), up 21.3%, Chelsea Therapeutics International ( CHTP), up 16.0% and PetMed Express ( PETS), up 13.6% , were all gainers within the health care sector with Onyx Pharmaceuticals ( ONXX) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)